Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses

Blood

Volumn 94, Issue 9, 1999, Pages 3234-3241

  Childs, R ^a   Clave, E ^a   Contentin, N ^a   Jayasekera, D ^a   Hensel, N ^a   Leitman, S ^a   Read, E J ^a   Carter, C ^a   Bahceci, E ^a   Young, N S ^a   Barrett, A J ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE;

ADULT; AGED; ALLOIMMUNITY; ARTICLE; BONE MARROW CELL; CHIMERA; CLINICAL ARTICLE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEMATOPOIESIS; HLA MATCHING; HUMAN; IMMUNE RESPONSE; MALE; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; T LYMPHOCYTE;

EID: 0033230960     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v94.9.3234.421k16_3234_3241     Document Type: Article

References (24)

1. Khouri IF, Keating M, Korbling M, Przepiorka D, Anderlini P, O'Brien S, Giralt S, Ippoliti C, von Wolff B, Gajewski J, Donato M, Claxton D, Ueno N, Andersson B, Gee A, Champlin R: Transplant lite: Induction of graft-versus-malignancy using fludarabine-based non-ablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancy. J Clin Oncol 8:2817, 1998
2. Slavin S, Nagler A, Naparstek E, Kapelusknik Y, Aker M, Civitalli G, Varadi G, Kirshbaum M, Ackerstein A, Samuel S, Amar A, Brautbar C, Ben-Tall O, Eldor A, Or R: Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91:756, 1998
3. Giralt S, Estey E, Albitar M, van Biesen K, Rondori G, Anderlini P, O'Brien S, Khouri I, Gajewski J, Mehra R, Claxton D, Andersson B, Beran M, Przepiorka D, Koller C, Kornblau S, Korbling M, Keating M, Kantarjian H, Champlin R: Engraftment of allogeneic hematopoietic progenitor cells with purine analog containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 89: 4531, 1997
4. McSweeny PA, Wagner JL, Maloney DG, Radich J, Shiruzu J, Bensinger WI, Bryant E, Chauncy TR, Flowers MED, Kauffman M, Minor CS, Nash RA, Blume K, Storb R: Outpatient PBSC allografts using immunosuppression with low-dose TBI before and cyclosporine (CSA) and mycophenolate mofetil (MMF) after transplant. Blood 92:518a, 1998 (suppl 1)
5. Spitzer TR, McAfee SL, Sackstein R, Toh HC, Saidman S, Weymouth D, Preffer F, Colby C, Sachs DH, Sykes M: Induction of mixed chimerism and potent anti-tumor responses following non-myeloablative conditioning therapy and HLA-matched and mismatched donor bone marrow transplantation (BMT) for refractory hematologic malignancies (HM). Blood 92:519a, 1998 (suppl 1)
6. Grigg A, Bardy P, Byron K, Seymour JF, Szer J: Fludarabine-based non-myeloablative chemotherapy followed by infusion of HLA-identical stem cells for relapsed leukaemia and lymphoma. Bone Marrow Transplant 23:107, 1999
7. McKinnon S, Barnett L, Heller G, O'Reilly RJ: Minimal residual disease is more common in patients who have mixed T-cell chimerism after bone marrow transplantation for chronic myelogenous leukaemia. Blood 83:3409, 1994
8. Roux E, Helg C, Dumont-Girard F, Chapuis B, Jeannet M, Roosnek E: Analysts of T-cell repopulation after allogeneic bone marrow transplantation: Significant differences between recipients of T-cell-depleted and unmanipulated grafts. Blood 87:3984, 1996
9. Gardiner N, Lawler M, O'Riordan J, DeArce M, Humphries P, McCann SR: Persistent donor chimerism is consistent with disease-free survival following BMT for chronic myeloid leukaemia. Blood 90: 1321, 1997
10. Roux E, Helg C, Chapuis B, Jeannet M, Roosnek E: Evolution of mixed chimerism after bone marrow transplantation as determined on granulocytes and mononuclear cells by the polymerase chain reaction. Blood 79:2775, 1992
11. Bader P, Beck J, Schlegel PG, Handgretinger R, Niethammer D, Klingebiel T: Additional immunotherapy on the basis of increasing mixed hematopoietic chimerism after allogeneic BMT in children with acute leukemia: Is there an option to prevent relapse? Bone Marrow Transplant 20:79, 1997
12. Landman-Parker J, Socie G, Petit T, Raynal B, Bourhis JH, Pico J, Brison O: Detection of recipient cells after non T cell depleted marrow transplantation for leukemia by the PCR amplification of minisatellites or of a Y chromosome marker has a different prognostic value. Leukemia 8:1989, 1994
13. Bolt DH, Von Hoff DD, Kuhn JG, Hersh M: Effect on human peripheral lymphocytes of in vivo administration of 9-β-D-arabinofuranosyl-fluoroadenine-5'-monophosphate (NSC312887) a new purine antimetabolite. Cancer Res 44:4661, 1984
14. Goodman ER, Fiedor PS, Fein S, Sung RS, Athan E. Hardy MA: Fludarabine phosphate and 2-chlorodeoxyadenosine: Immuno-suppressive DNA synthesis inhibitors with potential application in islet allo-xenotransplantation. Transplant Proc 27:3293, 1995
15. Barrett AJ, Mavroudis D, Tisdale J, Molldrem J, Clave E, Dunbar C, Cottler-Fox M, Phang S, Carter C, Okunnieff P, Young NS, Read EJ: T cell-depleted bone marrow transplantation and delayed T cell add-back to control acute GVHD and conserve a graft-versus-leukemia effect. Bone Marrow Transplant 21:1, 1998
16. Mackinnon S, BarnettL, Bourhis JH, Black P, Heller G, O'Reilly RJ: Myeloid and lymphoid chimerism after T-cell depleted bone marrow transplantation: Evaluation of conditioning regimens using the polymerase chain reaction to amplify human minisatellite regions of genomic DNA. Blood 80:3235, 1992
17. Agarwal R, Doren S, Hicks B, Dunbar CE: Long-term culture of chronic myelogeneous leukemia marrow cells on stem cell factor-deficient stroma favors benign progenitors. Blood 85:1306, 1995
18. Childs R, Clave E, Tisdale J, Plante M, Hensel N, Barrett AJ: Successful treatment of metastatic renal-cell carcinoma with a non-myeloablative allogeneic peripheral blood progenitor cell transplant: Evidence for a graft-versus-tumor effect. J Clin Oncol 17:2044, 1999
19. Reisner Y, Martelli MF: Bone marrow transplantation across HLA barriers by increasing the number of transplanted cells. Immunol Today 16:437, 1995
20. Kolb HJ, Schattenberg A, Goldman JM, Hertenstein B, Jacobsen N, Arcese W, Ljungman P, Ferrant A, Verdonck L, Niederwieser D, van Rhee F, Mittermuller J, de Witte T, Holler E, Ansari H: Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 86:2041, 1995
21. Rondon G, Giralt S, Huh Y, Khouri I, Anderson B, Andreeff M, Champlin R: Graft-versus-leukemia effect after allogeneic bone marrow transplantation for chronic lymphocytic leukemia. Bone Marrow Transplant 18:669, 1996
22. Ringden O, Horowitz MH, Gale RP, Biggs JC, Gajewski J, Rimm AA, Speck B, Veum-Stone JA, de Witte T, Bortin MM: Outcome after allogeneic bone marrow transplant for leukemia in older patients. JAMA 270:57, 1993
23. Klingemann HG, Storb R, Fefer A, Deeg HJ, Appelbaum F, Buckner CD, Cheever MA, Greenberg PD, Stewart PS, Sullivan KM, Witherspoon RP, Thomas ED: Bone marrow transplantation in patients aged 45 years and older. Blood 65:770, 1986
24. Frassoni F, Labopin M, Gluckman E, Prentice HG, Vernant JP, Zwaan F, Grañena A, Gahrton G, de Witte T, Gratwohl A, Reiffers J, Gorin N: Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time - A report of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 17:13, 1996